David Mintzer, MD
Hematology & Oncology · Philadelphia, PANPI 1487648846
Payments from drug & device makers
Across 67 payments — averaging $6629.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$206K
- Daiichi Sankyo Inc.$199K
- Genentech, Inc.$39K
- Servier Pharmaceuticals LLC$159
- GSK$35
- Clovis Oncology, Inc.$28
- plus $28 from 2 others
What the payments were for
- Food & beverage$7430%
- Education$17670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 5 | $205,757 |
| Daiichi Sankyo Inc. | 47 | $198,673 |
| Genentech, Inc. | 6 | $39,484 |
| Servier Pharmaceuticals LLC | 4 | $159 |
| GSK | 1 | $35 |
| Clovis Oncology, Inc. | 2 | $28 |
| Chiesi USA, Inc. | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$444,164 in reported general payments places this provider in the 85th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 35 | $503,206 |
| ImbruvicaIbrutinib | 27 | $424,431 |
| CalquenceAcalabrutinib Maleate | 34 | $415,113 |
| IbrancePalbociclib | 27 | $406,359 |
| JakafiRuxolitinib Phosphate | 21 | $354,729 |
| Lenalidomide | 21 | $343,755 |
| RevlimidLenalidomide | 16 | $332,592 |
| NubeqaDarolutamide | 29 | $282,741 |
| JaypircaPirtobrutinib | 12 | $197,102 |
| ErleadaApalutamide | 13 | $183,604 |
| VerzenioAbemaciclib | 14 | $155,451 |
| EliquisApixaban | 39 | $25,783 |
| XareltoRivaroxaban | 26 | $25,706 |
| Anastrozole | 192 | $6,495 |
| Enoxaparin Sodium | 16 | $4,872 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Philadelphia
- Stephen BagleyPhiladelphia$13.1M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
- Charu AggarwalPhiladelphia$7M
- Marcela MausPhiladelphia$4.4M
- Catherine LaiPhiladelphia$3.8M
- James StevensonPhiladelphia$3.4M
- Tara MitchellPhiladelphia$3.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.